glp-1 drugs glycemic control mechanism GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome The GLP-1 Agonists and Obesity:

By inhibiting NNMT, 5-Amino-1MQ may increase intracellular NAD+ levels and SAM availability, linking it to sirtuin activity, methylation capacity, and adipocyte differentiation research

Eventually, this excess fat spills over into the pancreas, damaging the beta cells responsible for insulin production and leading to prediabetes and, ultimately, type 2 diabetes

Homocysteine and holo-transcobalamin and the risk of dementia and Alzheimers disease: a prospective study

Stem Cell Signaling

Global warming and recurrent mass bleaching of corals

Fast tacrolimus metabolism does not promote post-transplant diabetes Mellitus after kidney transplantation